What is Organon's emgality — revenue?

Organon (OGN) reported emgality — revenue of $54M in Q1 2026.

How has Organon's emgality — revenue changed year-over-year?

Organon's emgality — revenue increased by 68.8% year-over-year, from $32M to $54M.

What does emgality — revenue mean?

This metric represents the total net sales generated from the Emgality/Ravvow product line within the company's pharmaceutical portfolio. It serves as a key indicator of market adoption and commercial performance for this specific therapeutic asset. Tracking these revenues helps investors assess the growth trajectory and competitive positioning of the company's specialty medicine offerings.

Organon (OGN) Emgality — Revenue

Screener

Other product segments

Nexplanon/Implanon NXT

$201M-19.0%

Other

$87M+11.5%

Zetia

$87M+2.4%

Atozet

$85M+10.4%

Other Non-Opiod Pain, Bone and Dermatology

$68M0.0%

Hadlima

$67M+42.6%

Nasonex

$65M-9.7%

Follistim AQ

$61M-11.6%

Arcoxia

$59M-4.8%

Cozaar/Hyzaar

$57M+3.6%

Renflexis

$57M0.0%

Other Women's Health

$46M+7.0%

Singulair

$40M-45.9%

Diprospan

$35M+16.7%

Dulera

$35M-18.6%

Clarinex

$31M-8.8%

Propecia

$30M+15.4%

Fosamax

$29M-12.1%

Other Cardiovascular

$28M-6.7%

Ganirelix Acetate Injection

$26M-3.7%

Marvelon/Mercilon

$26M-33.3%

Proscar

$26M+8.3%

Vtama

$25M+4.2%

NuvaRing

$24M+9.1%

Other Biosimilars

$24M—

Vytorin

$21M-8.7%

Brenzys

$20M+42.9%

Other Respiratory

$12M-7.7%

Rosuzet

$6M+50.0%

Jada

$5M-66.7%

Ontruzant

$5M-72.2%

Similar metrics at other companies

LENOther revenues — Revenue

$331.4M-6.8%

PRGOther Revenues — Revenue

$21.62M+165%

BDLOther Revenues — Revenue

$88K+27.5%

AEPCommercial Revenues — Revenue

$1.21B+15.4%

EQIXRecurring revenues — Revenue

$2.38B+10.9%

GCTProduct revenues — Revenue

$290.82M+28.9%

Other financials

Income statement

See full

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

See full

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

See full

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

See full

Market cap$3.56B+57.0%

Enterprise value$11.01B+4.2%

P/E6.6×+2.1×

P/S0.6×+0.2×

Profitability

See full

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

See full

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Organon’s 10-Q, filed May 4, 2026.

Filed: May 4, 2026, 8:46 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001628280-26-029532

($ in millions)	Three Months Ended March 31, 2025 / U.S.	2025 / Int’l	Total	U.S.	Int’l	Total
Other Non-Opioid Pain, Bone and Dermatology (1)	3	65	68	4	65	68
Other
Propecia	1	28	30	1	24	26
Emgality	—	54	54	—	32	32
Proscar	—	26	26	—	24	24
Other (1)	3	85	87	3	76	78
Other (2)	—	18	18	—	22	22
Revenues	$358	$1,102	$1,460	$412	$1,101	$1,513

Item 1. Financial Statements (unaudited)

FAQ

What is Organon's emgality — revenue?: Organon (OGN) reported emgality — revenue of $54M in Q1 2026.
How has Organon's emgality — revenue changed year-over-year?: Organon's emgality — revenue increased by 68.8% year-over-year, from $32M to $54M.
What does emgality — revenue mean?: This metric represents the total net sales generated from the Emgality/Ravvow product line within the company's pharmaceutical portfolio. It serves as a key indicator of market adoption and commercial performance for this specific therapeutic asset. Tracking these revenues helps investors assess the growth trajectory and competitive positioning of the company's specialty medicine offerings.